{"id":"W4410049939","doi":"10.1016/j.clml.2025.04.020","title":"Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Takeda Pharmaceuticals U.S.A.; Takeda Development Center Americas","keywords":"Medicine; Internal medicine; Rituximab; Chills; Phases of clinical research; Pharmacodynamics; Gastroenterology; Lymphoma; Refractory (planetary science); Adverse effect; Oncology; Dosing; Pharmacology; Immunology; Toxicity; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001137029,0.0004118622,0.001384658,0.0008419147,0.00013151,0.0000285748,0.0003023951,0.0003625647,0.00008456012],"category_scores_gemma":[0.0008589771,0.0003651077,0.0002450511,0.001439555,0.0002622651,0.0002056488,0.000166837,0.0004770967,0.00003138194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001477402,"about_ca_system_score_gemma":0.00183709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001243631,"about_ca_topic_score_gemma":0.0009649692,"domain_scores_codex":[0.9956414,0.0003283384,0.002172005,0.0008548169,0.0005115857,0.0004918845],"domain_scores_gemma":[0.9971426,0.0009641256,0.0004917009,0.0008692125,0.0003320914,0.0002003417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01302767,0.09714504,0.1378733,0.0002217406,0.0003063051,0.000955854,0.001617801,0.00005615117,0.005386492,0.0004638122,0.001592117,0.7413537],"study_design_scores_gemma":[0.144165,0.02012595,0.8230048,0.001217832,0.0001996972,0.00004210023,0.001442845,0.003361205,0.002912703,0.0001690468,0.003015882,0.0003430081],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939055,0.0001418377,0.0001132295,0.0003237914,0.0005526291,0.001295183,0.00001719198,0.00008171644,0.003568917],"genre_scores_gemma":[0.9982051,0.00004912369,0.0002957899,0.0004783296,0.000102044,0.0001307701,0.00006376425,0.0000542042,0.0006209097],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7410107,"threshold_uncertainty_score":0.9998801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02805496074734917,"score_gpt":0.3550067574628266,"score_spread":0.3269517967154774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}